Erythropoiesis Stimulating Agents (ESAs) not allowed in new DAA trials?

Some field intelligence reveals that Erythropoiesis Stimulating Agents (ESAs) are not being allowed in some of  current clinical HCV trials sponsored by Roche, BI, and Tibotec.  If this is true, and ESAs are not needed with these new compounds in development, the life cycle for Schmerck's Boceprevir may be very, very short. Good thing they now have plenty of ammo in the pipeline.